OverviewSuggest Edit

Aratana Therapeutics is a pioneer in pet therapeutics focused on licensing, developing and commercializing innovative therapeutics for dogs and cats. Its goal is to provide veterinarians and pet owners with new therapeutics that are driven by science and specifically made for pets. The Сompany's pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions. Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.

TypePublic
Founded2010
HQLeawood, US
Websitearatana.com
Employee Ratings0

Latest Updates

Employees (est.) (Feb 2019)84
Job Openings1
Revenue (FY, 2018)$35.4 M(+39%)
Share Price (Mar 2019)$3.7 (-4%)

Key People/Management at Aratana Therapeutics

Louise MawHinney

Louise MawHinney

CFO
Ernst Heinen

Ernst Heinen

Head of Drug Evaluation and Development
John Ayers

John Ayers

General Counsel & Secretary
James Miller

James Miller

Controller
Marie-Paul Lachaud

Marie-Paul Lachaud

Head of Business & Product Development Europe
Show more

Aratana Therapeutics Office Locations

Aratana Therapeutics has offices in Leawood, San Diego and Leuven
Leawood, US (HQ)
11400 Tomahawk Creek Pkwy #340
San Diego, US
10451 Roselle St #200a
Leuven, BE
1 Ambachtenlaan
Show all (3)
Report incorrect company information

Aratana Therapeutics Financials and Metrics

Aratana Therapeutics Revenue

Aratana Therapeutics's revenue was reported to be $35.41 m in FY, 2018
USD

Revenue (FY, 2018)

35.4m

Gross profit (FY, 2018)

28.6m

Gross profit margin (FY, 2018), %

80.8%

Net income (FY, 2018)

(14.7m)

EBIT (FY, 2018)

(11.9m)

Market capitalization (22-Mar-2019)

179.7m

Closing stock price (22-Mar-2019)

3.7

Cash (31-Dec-2018)

41.4m
Aratana Therapeutics's current market capitalization is $179.7 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

123.0k767.0k678.0k38.6m25.6m35.4m

Revenue growth, %

524%(12%)5586%

Cost of goods sold

108.0k365.0k3.1m16.4m6.8m

Gross profit

15.0k313.0k35.4m9.2m28.6m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

176.0k300.0k43.0k156.0k230.0k229.0k172.0k38.0m40.0k3.8m5.2m6.2m4.0m4.9m21.6m

Cost of goods sold

110.0k109.0k138.0k19.0k1.7m286.0k3.1m3.7m3.7m536.0k1.3m2.2m

Gross profit

46.0k121.0k91.0k153.0k36.3m(246.0k)701.0k1.5m2.5m3.5m3.6m19.4m

Gross profit Margin, %

29%53%40%89%95%(615%)18%28%40%87%73%90%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

41.1m9.8m26.8m87.3m66.9m41.4m

Accounts Receivable

352.0k60.0k87.0k2.4m2.2m

Inventories

55.0k427.0k1.3m11.1m13.6m11.4m

Current Assets

48.5m99.9m89.0m101.5m85.2m58.1m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

46.2m76.7m68.3m56.8m30.2m12.6m13.5m13.8m108.8m100.8m67.5m78.8m68.8m66.4m59.3m54.3m

Accounts Receivable

147.0k387.0k90.0k115.0k148.0k134.0k11.0k17.0k15.0k3.5m4.9m9.4m2.4m2.8m19.6m

Inventories

125.0k124.0k203.0k645.0k882.0k1.2m2.4m2.6m5.6m9.1m7.0m9.0m14.0m15.2m13.7m

Current Assets

52.6m82.3m73.4m110.5m89.4m85.7m75.3m77.1m113.7m110.9m81.9m98.8m90.7m84.6m79.0m91.1m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(4.3m)(38.8m)(84.1m)(33.6m)(47.5m)(14.7m)

Depreciation and Amortization

395.0k2.0m1.8m991.0k1.2m990.0k

Inventories

(372.0k)(879.0k)(15.0m)(3.2m)(499.0k)

Accounts Payable

1.5m(1.1m)(117.0k)6.2m62.0k(6.5m)
USDY, 2018

Revenue/Employee

421.6k

Financial Leverage

1.1 x
Show all financial metrics
Report incorrect company information

Aratana Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Aratana Therapeutics News and Updates

Aratana Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

LEAWOOD, Kan., March 12, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, announced its fourth quarter and full year 2018 financial results and recent...

Aratana Therapeutics to Participate at Upcoming Investment Conferences

LEAWOOD, Kan., Feb. 13, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, plans on attending the following upcoming investment conferences: Bank of...

Aratana Therapeutics Appoints Rhonda Hellums Chief Financial Officer

LEAWOOD, Kan., Feb. 4, 2019 /PRNewswire/ -- Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the development and commercialization of innovative therapeutics for dogs and cats, today announced the appointment of Rhonda Hellums as Chief Financial Officer and ...

Global Veterinary Clostridium Vaccines Market : Key Players are Elanco, Merck, Merial, Zoetis, Advaxis, MPLIPHI, Aratana Therapeutics, ARKO Labs

Veterinary Clostridium Vaccines Market report provides in-depth statistics and analysis available on the market status of the Veterinary Clostridium Vaccines Manufacturers and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Veter…

Aratana Therapeutics to Report Third Quarter 2018 Financial Results

LEAWOOD, Kan., Oct. 22, 2018 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative therapeutics for dogs and cats, will host a live conference call on Friday, November 2, 2018 at 8:30 ...
Report incorrect company information

Aratana Therapeutics Blogs

Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results

The Company will host a live conference call on Tuesday, March 12, 2019 at 4:30 p.m. ET to discuss financial results from the fourth quarter and full year ended December 31, 2018. The post Aratana Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results appeared first on Aratana Th…

Aratana Therapeutics’ Board of Directors Appoints Craig Tooman Chief Executive Officer

The Company announced today the Company’s Board of Directors has appointed Craig Tooman to serve as President and Chief Executive Officer of Aratana, and elected Tooman to the Board of Directors. The post Aratana Therapeutics’ Board of Directors Appoints Craig Tooman Chief Executive Officer appeared…

Aratana Therapeutics Reports Third Quarter 2018 Financial Results

For the third quarter ended September 30, 2018, Aratana reported total net revenues of $21.6 million and net income of $8.8 million or $0.19 diluted earnings per share. The net revenues for the quarter included a $15.0 million commercial milestone, which resulted in profitability for the quarter. T…

Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference

The Company plans on presenting at CL King & Associates Best Ideas Conference on Thursday, September 13, 2018 at 1:15 p.m. ET in New York City. The post Aratana Therapeutics to Present at CL King and Associates Best Ideas Conference appeared first on Aratana Therapeutics.

NOCITA® (bupivacaine liposome injectable suspension)

The U.S. Food and Drug Administration’s Center for Veterinary Medicine (CVM) approved the supplemental New Animal Drug Application (NADA) to expand the NOCITA label. The post NOCITA® (bupivacaine liposome injectable suspension) appeared first on Aratana Therapeutics.

Aratana Therapeutics Reports Second Quarter 2018 Financial Results

The Company announced its second quarter 2018 financial results and will host a live conference call on Friday, August 3, 2018 at 8:30 a.m. ET to discuss financial results from the quarter ended June 30, 2018. The post Aratana Therapeutics Reports Second Quarter 2018 Financial Results appeared firs…
Show more

Aratana Therapeutics Frequently Asked Questions

  • When was Aratana Therapeutics founded?

    Aratana Therapeutics was founded in 2010.

  • Who are Aratana Therapeutics key executives?

    Aratana Therapeutics's key executives are Louise MawHinney, Ernst Heinen and John Ayers.

  • How many employees does Aratana Therapeutics have?

    Aratana Therapeutics has 84 employees.

  • What is Aratana Therapeutics revenue?

    Latest Aratana Therapeutics annual revenue is $35.4 m.

  • What is Aratana Therapeutics revenue per employee?

    Latest Aratana Therapeutics revenue per employee is $421.6 k.

  • Who are Aratana Therapeutics competitors?

    Competitors of Aratana Therapeutics include Rigel Pharmaceuticals, Rodeo Therapeutics and BlackThorn Therapeutics.

  • Where is Aratana Therapeutics headquarters?

    Aratana Therapeutics headquarters is located at 11400 Tomahawk Creek Pkwy #340, Leawood.

  • Where are Aratana Therapeutics offices?

    Aratana Therapeutics has offices in Leawood, San Diego and Leuven.

  • How many offices does Aratana Therapeutics have?

    Aratana Therapeutics has 3 offices.